Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > A/O Sept. 08th ONCY's cash runway is until late Q4, 2024

<< Previous

Bullboard Posts

Next >>

Comment by JohnnyYegon Sep 09, 2023 1:00pm

147 Views

Post# 35627701

RE:A/O Sept. 08th ONCY's cash runway is until late Q4, 2024

And what are the chances that with ONCY running two P3s that have shown success and efficacy to this point in former trials, that they actually see the end of Q4 as ONCY and "cash runway" remains a concern??

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario